NEWS

Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University

Melbourne (Australia) and Osaka (Japan) – 27 April 2020. Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry technology.

Telix Pharmaceuticals Limited is pleased to announce it has concluded an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry technology.

The licensed technology is the outcome of a research collaboration established between Telix and Osaka University in 2018 to develop second-generation variants of TLX101 (131I-IPA) that may be suitable for certain advanced cancer therapy applications.

The newly developed radiochemistry enables the production of TLX101 with high production efficiency as well as astatine-211 (211At) variants, which may be suitable for other cancer indications.

To read the full media release please click here.